BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22740881)

  • 1. Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine.
    Erguven M; Bilir A; Yazihan N; Korkmaz S; Aktas E; Ovalioglu C; Dundar T; Seyithanoglu H
    Oncol Lett; 2012 Jan; 3(1):200-208. PubMed ID: 22740881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonist activity of the antipsychotic drug lithium chloride and the antileukemic drug imatinib mesylate during glioblastoma treatment in vitro.
    Aras Y; Erguven M; Aktas E; Yazihan N; Bilir A
    Neurol Res; 2016 Sep; 38(9):766-74. PubMed ID: 27367429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine.
    Erguven M; Bilir A; Yazihan N; Ermis E; Sabanci A; Aktas E; Aras Y; Alpman V
    Cancer Cell Int; 2011 Jun; 11(1):18. PubMed ID: 21651812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib and lithium chloride combination treatment shows promising synergistic effects in human glioblastoma multiforme cells in vitro but midkine is not implicated.
    Sabancι PA; Ergüven M; Yazιhan N; Aktaş E; Aras Y; Civelek E; Aydoseli A; Imer M; Gürtekin M; Bilir A
    Neurol Res; 2014 Mar; 36(3):189-97. PubMed ID: 24512012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro.
    Bilir A; Erguven M; Ermis E; Sencan M; Yazihan N
    J Gynecol Oncol; 2011 Dec; 22(4):225-32. PubMed ID: 22247798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation.
    Ranza E; Mazzini G; Facoetti A; Nano R
    J Neurooncol; 2010 Feb; 96(3):349-57. PubMed ID: 19629393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human embryonic stem cells display a pronounced sensitivity to the cyclin dependent kinase inhibitor Roscovitine.
    Videla-Richardson GA; Furmento VA; Garcia CP; Morris-Hanon O; Sevlever GE; Romorini L; Scassa ME
    BMC Mol Cell Biol; 2019 Aug; 20(1):40. PubMed ID: 31462218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells.
    Komina O; Wesierska-Gadek J
    Biochem Pharmacol; 2008 Dec; 76(11):1554-62. PubMed ID: 18761329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells.
    Wesierska-Gadek J; Kramer MP; Maurer M
    Food Chem Toxicol; 2008 Apr; 46(4):1327-33. PubMed ID: 17933449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ornithine decarboxylase alters the roscovitine-induced mitochondrial-mediated apoptosis in MCF-7 breast cancer cells.
    Arisan ED; Obakan P; Coker A; Palavan-Unsal N
    Mol Med Rep; 2012 May; 5(5):1323-9. PubMed ID: 22344475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced anticancer activity of combined treatment of imatinib and dipyridamole in solid Ehrlich carcinoma-bearing mice.
    El-Sisi AE; Sokar SS; Ibrahim HA; Abu-Risha SE
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Jun; 393(6):1113-1129. PubMed ID: 31950222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
    Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
    J Cell Biochem; 2011 Mar; 112(3):761-72. PubMed ID: 21328450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: Involvement of COX-2, Caspase-3, VEGF and NF-κB genes expression.
    Atari-Hajipirloo S; Nikanfar S; Heydari A; Noori F; Kheradmand F
    Cell Mol Biol (Noisy-le-grand); 2016 Feb; 62(2):68-74. PubMed ID: 26950454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carvedilol in glioma treatment alone and with imatinib in vitro.
    Erguven M; Yazihan N; Aktas E; Sabanci A; Li CJ; Oktem G; Bilir A
    Int J Oncol; 2010 Apr; 36(4):857-66. PubMed ID: 20198329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of anti-estrogen combined with roscovitine, a selective CDK inhibitor, on human breast cancer cells differing in expression of ER.
    Zulehner N; Maurer M; Wesierska-Gadek J
    J Exp Ther Oncol; 2011; 9(1):17-25. PubMed ID: 21275262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomes from mesenchymal stromal cells enhance imatinib-induced apoptosis in human leukemia cells via activation of caspase signaling pathway.
    Liu Y; Song B; Wei Y; Chen F; Chi Y; Fan H; Liu N; Li Z; Han Z; Ma F
    Cytotherapy; 2018 Feb; 20(2):181-188. PubMed ID: 29269240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells.
    Wesierska-Gadek J; Schreiner T; Gueorguieva M; Ranftler C
    J Cell Biochem; 2006 Aug; 98(6):1367-79. PubMed ID: 16741967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen enhances the anti-proliferative effect of roscovitine, a selective cyclin-dependent kinase inhibitor, on human ER-positive human breast cancer cells.
    Gritsch D; Maurer M; Zulehner N; Wesierska-Gadek J
    J Exp Ther Oncol; 2011; 9(1):37-45. PubMed ID: 21275264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells.
    Wesierska-Gadek J; Wandl S; Kramer MP; Pickem C; Krystof V; Hajek SB
    J Cell Biochem; 2008 Dec; 105(5):1161-71. PubMed ID: 18846503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.